Federal Register / Vol. 79, No. 199 / Wednesday, October 15, 2014 / Notices 61871 

concerning the proposed collection of 

information are encouraged. Your 

comments should address any of the 

following: (a) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (b) Evaluate the 

accuracy of the agencies estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; (d) Minimize the burden of 

the collection of information on those 

who are to respond, including through 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and (e) Assess information 

collection costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Written 

comments and/or suggestions regarding 

the items contained in this notice 

should be directed to the Attention: 

CDC Desk Officer, Office of Management 

and Budget, Washington, DC 20503 or 

by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Annual Survey of the National Breast 

and Cervical Cancer Early Detection 

Program (NBCCEDP) Grantees—New— 

National Center for Chronic Disease 

Prevention and Health Promotion 

(NCCDPHP), Centers for Disease Control 

and Prevention (CDC). 

Background and Brief Description 

To improve access to cancer 

screening, Congress passed the Breast 

and Cervical Cancer Mortality 

Prevention Act of 1990 (Pub. L. 101– 

354) which directed CDC to create the 

National Breast and Cervical Cancer 

Early Detection Program (NBCCEDP). 

Currently, the NBCCEDP funds 67 

grantees including all 50 states, the 

District of Columbia, 5 U.S. territories, 

and 11 American Indian/Alaska Native 

tribes or tribal organizations. Grantees 

provide screening services for breast 

and cervical cancer to low-income, 

uninsured, and underinsured women 

who otherwise would not have access to 

screening. 

The NBCCEDP is shifting from a focus 

on direct service provision to 

implementation of expanded evidencebased activities intended to increase 

rates of breast and cervical cancer 

screening at the population level. 

Though NBCCEDP grantees continue to 

provide breast and cervical cancer 

screening for un- and underinsured 

women, CDC is encouraging the 

implementation of strategies to increase 

screening rates beyond that of programeligible women. This data collection is 

being proposed in order to assess 

program implementation, particularly 

related to these expanded populationbased efforts. A survey of NBCCEDP 

grantees was originally fielded in Fall/ 

Winter 2013–2014 and cleared under 

0920–0879 as ‘‘Assess Breast and 

Cervical Cancer Screening Program 

Activities to Expand Access to 

Screening’’. The survey was found to be 

useful by CDC and the awardees (which 

received feedback reports). For example, 

after the initial implementation of last 

year’s survey, CDC was able to tailor 

sessions at the Program Director’s 

meeting to the needs of grantees that 

had been expressed during last year’s 

information collection. DCPC has 

decided to continue the data collection 

as an annual survey. Questions are of 

various types including dichotomous 

and multiple response. 

This assessment will enable CDC to 

gauge its progress in meeting NBCCEDP 

program goals, identify implementation 

activities, monitor program transition to 

efforts aimed at impacting populationbased screening, identify technical 

assistance needs of state, tribe and 

territorial health department cancer 

control programs, and identify 

implementation models with potential 

to expand and transition to new settings 

to increase program impact and reach. 

The assessment will identify successful 

activities that should be maintained, 

replicated, or expanded as well as 

provide insight into areas that need 

improvement. 

OMB approval is requested for three 

years. Participation is voluntary for 

NBCCEDP awardees and there are no 

costs to respondents other than their 

time. The estimated burden per 

response is 40 minutes and the total 

estimated annualized burden hours are 

45. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hrs.) 

Breast and Cervical Cancer 

Program Directors.

Annual Survey of the National Breast and Cervical Cancer 

Early Detection Program (NBCCEDP) Grantees’ Program 

Implementation.

67 1 40/60 

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2014–24438 Filed 10–14–14; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Breast and Cervical Cancer Early 

Detection and Control Advisory 

Committee (BCCEDCAC) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC), 

announces the following meeting of the 

aforementioned committee: 

Times and Dates: 9:00 a.m.–5:00 p.m., EST, 

November 6, 2014. 9:00 a.m.–12:30 p.m. EST, 

November 7, 2014. 

Place: CDC, 2900 Woodcock Boulevard, 

University Office Park, Columbia Building, 

Room 1064/1065, Atlanta, Georgia 30341. 

Teleconference login information is as 

follows: 

For Participants: 

TOLL-FREE PHONE #: 800–988–9707. 

Participant passcode: 4798. 

For Participants: 


tkelley on DSK3SPTVN1PROD with NOTICES
61872 Federal Register / Vol. 79, No. 199 / Wednesday, October 15, 2014 / Notices 

URL: https://www.mymeetings.com/nc/

join/. 

Conference number: PW8992754. 

Audience passcode: 4798. 

Participants can join the event directly at: 

https://www.mymeetings.com/nc/

join.php?i=PW8992754&p=4798&t=c. 

There is also a toll number for anyone 

outside of the USA: 

TOLL PHONE #: 1 (312) 470–7387. 

Participant passcode: 4798. 

Status: Open to the public, limited only by 

space and net conference and audio phone 

lines available. 

Purpose: The committee is charged with 

advising the Secretary, Department of Health 

and Human Services, and the Director, CDC, 

regarding the early detection and control of 

breast and cervical cancer. The committee 

makes recommendations regarding national 

program goals and objectives; 

implementation strategies; and program 

priorities including surveillance, 

epidemiologic investigations, education and 

training, information, dissemination, 

professional interactions and collaborations, 

and policy. 

Matters for Discussion: The agenda will 

include: (1) Discussing the impact of 

implementation of the Affordable Care Act 

on the National Breast and Cervical Cancer 

Early Detection Program (NBCCEDP); (2) 

assessing the needs of the public and impact 

to the NBCCEDP; (3) population-based 

activities to increase appropriate screening; 

(4) screening communication tools; (5) 

provider risk assessments. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Jameka R. Blackmon, MBA, CMP, Designated 

Federal Officer, National Center for Chronic 

Disease Prevention and Health Promotion, 

CDC, 4770 Buford Highway NE., Mailstop 

F76, Atlanta, Georgia 30341, Telephone (770) 

488–4880. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Claudette Grant, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. 2014–24442 Filed 10–14–14; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2014–N–1491] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request; Survey of 

Pharmacists and Patients; Variations 

in the Physical Characteristics of 

Generic Drug Pills and Patients’ 

Perceptions 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

opportunity for public comment on the 

proposed collection of certain 

information by the Agency. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal Agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information and to allow 60 days for 

public comment in response to the 

notice. This notice solicits comments on 

the information collection associated 

with a survey of pharmacists and 

patients about their experiences 

resulting from changes in generic drug 

pill appearance. 

DATES: Submit either electronic or 

written comments on the collection of 

information by December 15, 2014. 

ADDRESSES: Submit electronic 

comments on the collection of 

information to http://

www.regulations.gov. Submit written 

comments on the collection of 

information to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, Rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: FDA 

PRA Staff, Office of Operations, Food 

and Drug Administration, 8455 

Colesville Rd., COLE–14526, Silver 

Spring, MD 20993–0002, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

Agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of information’’ is defined 

in 44 U.S.C. 3502(3) and 5 CFR 

1320.3(c) and includes Agency requests 

or requirements that members of the 

public submit reports, keep records, or 

provide information to a third party. 

Section 3506(c)(2)(A) of the PRA (44 

U.S.C. 3506(c)(2)(A)) requires Federal 

Agencies to provide a 60-day notice in 

the Federal Register concerning each 

proposed collection of information 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology. 

Survey of Pharmacists and Patients: 

Variations in the Physical 

Characteristics of Generic Drug Pills 

and Patients’ Perceptions—(OMB 

Control Number 0910–NEW) 

Generic drugs make up approximately 

85 percent of all human prescription 

drugs prescribed in the United States. 

While generic drugs are required to be 

pharmaceutically equivalent and 

bioequivalent to their brand-name 

counterparts, generics made by different 

manufacturers may differ substantially 

from their brand-name therapeutic 

equivalents and from each other in their 

physical appearance (e.g., color, shape, 

or size of pills). When pharmacists 

switch generic drug suppliers, patients 

refilling their generic prescriptions may 

therefore experience changes in their 

drugs’ appearances. These changes may 

result in patient confusion and concerns 

about the safety and effectiveness of the 

generic drug products. Studies indicate 

that patients are more likely to stop 

taking their generic medications when 

they experience a change in their drugs’ 

physical appearances, leading to 

harmful clinical and public health 

consequences as well as increased 

health care costs from avoidable 

morbidity and mortality. 

To provide additional information 

that may help guide regulatory policy or 

pharmacy business practices, we intend 

to conduct surveys of pharmacists and 

patients about their perceptions about 

and experiences with generic drug 


tkelley on DSK3SPTVN1PROD with NOTICES